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Recent advancement in genome engineering technology is changing the landscape of
biological research and providing neuroscientists with an opportunity to develop new
methodologies to ask critical research questions. This advancement is highlighted by
the increased use of programmable DNA-binding agents (PDBAs) such as transcription
activator-like effector (TALE) and RNA-guided clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR associated (Cas) systems. These PDBAs fused
or co-expressed with various effector domains allow precise modification of genomic
sequences and gene expression levels. These technologies mirror and extend beyond
classic gene targeting methods contributing to the development of novel tools for basic
and clinical neuroscience. In this Review, we discuss the recent development in genome
engineering and potential applications of this technology in the field of neuroscience.
Keywords: ZFN, TALE, TALEN, CRISPR, Cas9, genome engineering, neuroscience
INTRODUCTION
The relationship between genotype and phenotype is often not direct and one-to-one (Hirschhorn
and Daly, 2005; Manolio et al., 2009). In clinical settings, analyzing patients’ whole genome
sequencing data and triaging the significance of a variant remain a challenging task (MacArthur
et al., 2014; Shendure, 2014; Richards et al., 2015). This is especially the case for neural
or behavioral phenotypes. Many neuropsychiatric disorders are multi-genic or multi-factorial
involving complex gene-gene or gene-environment interactions (Franke et al., 2009; Sullivan et al.,
2012; Dunn et al., 2015). Disease manifestations of neuronal diseases, whether neuropsychiatric
or neurodegenerative, are often circuit- or neuronal population-specific making circuit-level
understanding indispensable in neuroscience (Shin and Liberzon, 2009; Russo and Nestler, 2013;
Shepherd, 2013). Neuronal subtypes are diverse, and each type may show distinct structural,
functional, electrophysiological, and connectional properties. Different methods estimate the
number of neuronal subtypes in the brain from∼100 to 1000 (Stevens, 1998; Masland, 2001, 2004;
Nelson et al., 2006). Different epigenetic landscapes endow a distinct identity to each neuronal
subtype that arises from a common genome within each organism. This epigenetic encoding could
be the substrate in which the gene-environment interaction is consolidated (Vialou et al., 2013).
Interrogating such complexity in the nervous system requires sophisticated methodologies that
can manipulate each component while minimizing the perturbation of the whole system. Recently
developed genome engineering technologies allow genomic perturbations with surgical precision,
and these technologies are well-suited for advancing neuroscience.
There are several advantages to genome engineering technologies. First, programmable DNA-
binding agents (PDBAs) can be targeted to any locus in the genome. Particularly, transcription
activator-like effector (TALE) and clustered regularly interspaced short palindromic repeats
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(CRISPR)/CRISPR associated (Cas) systems can be targeted at
nucleotide resolution. Second, a variety of effectors can be fused
to the PDBA as a module. PDBAs fused to endonucleases make
breaks in the DNA that can introduce random or targeted DNA
changes when co-delivered with exogenous DNA sequences.
With transcription activators and repressors, or epigenetic
modifiers, gene expression can be up- or down-regulated. Using
fluorescent proteins as an effector, specific genomic loci can be
visualized in live cells or animals allowing for structural and
organizational investigations of chromatin. Third, PDBAs can
be used for therapeutic purposes with applications ranging from
correctingmutations inmonogenic disorders tomodulating gene
expression. In this Review, we discuss recent developments in
genome engineering and their potential applications in the field
of neuroscience. We summarize the use of PDBAs as (1) genome
editing tools and (2) gene expression modulators, and discuss (3)
other considerations in applying these systems in neuroscience.
GENOME EDITING WITH CUSTOMIZABLE
ENDONUCLEASES
The field of genome engineering has developed over the past
several decades. Classic gene targeting that has established
mutant mouse models was the first to show that biological
functions of the genes can be perturbed and studied in vivo
(Evans and Kaufman, 1981; Smithies et al., 1985; Thomas
and Capecchi, 1986). Around the same time, investigations
into nonhomologous end joining (NHEJ) and homologous
recombination (HR) were defining and uncovering DNA repair
pathways (Roth and Wilson, 1985; Lehman et al., 1993; Phillips
and Morgan, 1994; Hagmann et al., 1996). The biology of gene
targeting andDNA repair mechanisms were gradually elucidated,
uncovering critical variables for genome engineering such as
linear donor DNA is more recombinogenic than circular ones
(Orr-Weaver et al., 1981; Folger et al., 1982; Rong and Golic,
2001) or a DNA double-strand break (DSB) in the genome
increases the rate of HR (Puchta et al., 1993; Rouet et al., 1994;
Choulika et al., 1995; Smih et al., 1995). The structural studies and
engineering of zinc finger protein led to the development of first
programmable DNA binding agents (Pavletich and Pabo, 1991;
Desjarlais and Berg, 1992; Choo and Klug, 1994; Wu et al., 1995;
Kim et al., 1996; Smith et al., 2000).
Zinc Finger Nucleases (ZFNs)
The zinc finger nuclease (ZFN) was introduced in 1996 to address
the need for more specific restriction endonucleases (Kim et al.,
1996). Repeated zinc finger DNA-binding domains were fused to
a FokI endonuclease domain to allow for programmable DNA
sequence binding specificity as each finger motif moves along
the major groove of the DNA double helix and stabilizes upon
binding three matching base pairs (Kim et al., 1996).
In the early 1990s it was shown that HR increased by two- to
four- orders of magnitude in plant and mammalian cells when a
double-strand break (DSB) was introduced to the genome by the
rare-cutting endonuclease, I-SceI (Puchta et al., 1993; Rouet et al.,
1994; Choulika et al., 1995; Smih et al., 1995). Exploiting this, a
collaboration between Chandrasegaran and Carroll labs showed
that HR could be significantly increased when ZFNs made DSBs
in the genome (Bibikova et al., 2001).
Subsequent refinement of ZFNs provided a template for
innovation of next generation genome engineering tools–
TALENs and CRISPR/Cas9. For example, modified FokI catalytic
domains, which increased specificity or efficiency, were first
developed for ZFN applications and later adapted for TALENs.
Obligate heterodimeric versions of FokI significantly decreased
off-target effects and genome toxicity caused by unintended
homodimerization (Miller et al., 2007; Szczepek et al., 2007).
Guo et al. used directed evolution to select for increased FokI
activity, improving mutagenic efficiency by three- to six-fold
(Guo et al., 2010). A zinc finger nickase system had been shown to
favor homology-directed repair (HDR) without activating NHEJ
repair, minimizing opportunities for errors and off-target effects
(Kim et al., 2012; Ramirez et al., 2012). A nickase commonly
refers to an endonuclease that generates a single-strand DNA
break, nick.
ZFNs have been widely used to create animal models and
are currently the only genome editing tool being utilized in
clinical settings. Studies addressing diseases such as Huntington’s
disease (Garriga-Canut et al., 2012) and Hurler and Hunter
syndromes (Sharma et al., 2015) are in pre-clinical development,
and HIV treatments have reached early clinical trials (Perez et al.,
2008; Wilen et al., 2011; Tebas et al., 2014; for a review, see
Jo et al., 2015). ZFN research is now focused on improving
delivery methods. Despite the pioneering role of ZFNs, difficulty
of designing and optimizing the ZFN reagents (Greisman and
Pabo, 1997) led to rapid adaptation of first TALEN and then
CRISPR/Cas9 systems.
Transcription Activator-Like Effector
Nucleases (TALENs)
The DNA-binding mechanism of TALEs was elucidated in 2009
(Boch et al., 2009; Moscou and Bogdanove, 2009), years after the
discovery of TALEs as secreted proteins from the bacterial plant
pathogen Xanthomonas (Bai et al., 2000; Yang and White, 2004;
Gu et al., 2005; Kay et al., 2007; Sugio et al., 2007). Native TALEs
are comprised of an N-terminal domain, central repeats of the
DNA binding domain, a C-terminal segment that incorporates
nuclear localization signals, and a transcriptional activation
domain (Bogdanove et al., 2010). The DNA-binding domain
consists of 33–35 amino acid repeats with differences at residues
12 and 13 (repeat variable di-residue; RVD). A specific RVD in
the DNA-binding domain recognizes a base in the target locus,
providing a structural feature to assemble predictable DNA-
binding domains. TheDNA binding domains of a TALE are fused
to the catalytic domain of a type IIS FokI endonuclease to make
a targetable TALE nuclease (TALEN; Figure 1A). To induce site-
specific mutation, two individual TALEN arms, separated by a
14–20 base pair spacer region, bring FokI monomers in close
proximity to dimerize and produce a targeted DSB (Figure 1A).
Several modifications to the native TALE composition and
initial TALEN design have improved binding and cleavage
specificity and efficiency (Christian et al., 2010; Hockemeyer
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FIGURE 1 | DNA-binding agents, DNA double-strand break (DSB) and repair pathways. (A) A pair of TALEN monomers bound to double-strand DNA. A
TALEN monomer comprises N-terminal domain, nuclear localization signal, modular repeats that contain two highly variable amino acid residues (RVDs), C-terminal
domain, and FokI endonuclease. TALENs bind to target DNA in the major groove. A pair of TALEN monomers targeted closely enable FokI dimerization to make DNA
double-strand break. Cas9 protein and sgRNA form a complex. The sgRNA-Cas9 complex bind to target DNA through Watson-Crick base-pairing between the target
recognition region of the sgRNA and the target DNA sequence (protospacer). The target recognition region (pink rectangle) is the RNA sequence in the sgRNA that
matches the target DNA sequence (20 nt). The PAM (protospacer adjacent motif) sequence varies depending on the type of Cas protein. Streptococcus pyogenes
Cas9 protein recognizes 5′-NGG-3′ sequence. (B) Targetable TALEN and CRISPR/Cas9 systems generate DNA double-strand break (DSB) at the target locus in the
genome. DSBs are repaired by non-homologous end joining (NHEJ), homology-directed repair (HDR), or homologous recombination (HR). Error-prone NHEJ results in
non-functional proteins or loss of protein through frameshift mutations introduced to open reading frame. HDR and HR mediate faithful repair of DNA break by
incorporating exogenously provided DNA templates in either single strand DNA oligos (ssDNA donor) or plasmids (dsDNA donor). HDR and HR can be used to
change small sequences or tag the target gene with a reporter (e.g., green fluorescent protein). TALENs, transcription activator-like effector nucleases; NLS, nuclear
localization signal; RVD, repeat variable di-residue; FokI, FokI endonuclease; N-term, N-terminal domain; C-term, C-terminal domain; CRISPR/Cas9, clustered
regularly interspaced short palindromic repeats/CRISPR associated protein 9; sgRNA, single guide RNA; PAM, protospacer adjacent motif.
et al., 2011; Li et al., 2011; Tesson et al., 2011). In an
effort to improve TALEN efficiency, improved TALEN scaffolds
incorporated optimized nuclear localization sequences, amino-
terminal, and carboxy-terminal truncations, and assorted FokI
nuclease linkers (Mussolino and Cathomen, 2012). In vitro
scaffolding modifications have been studied by fusing variable C-
terminal truncations to the catalytic domain of FokI to determine
which variants enable efficient cleavage, the final modification
of which retained only 28 or 63 of the 278 original C-terminal
residues (Miller et al., 2011). Different TALEN scaffolds and
native TALEs from other bacterial species continue to be
tested and optimized to achieve a higher and more consistent
activity of targeting genetic modifications. Our lab has used
the GoldyTALEN scaffold to improve in vivo efficacy with a
messenger RNA expression vector backbone (pT3TS). When
using the GoldyTALEN scaffold, there was a six-fold increase
in somatic gene modification, and germline modification rate
increased from 17 to 71% (Bedell et al., 2012). Achieving a higher
level of TALEN activity can depend on the length (base pairs) of
the spacer between the two individual TALEN binding sites and
the specificity of DNA binding (Ma A. C. et al., 2013a).
Clustered Regularly Interspaced Short
Palindromic Repeats/CRISPR Associated
(CRISPR/Cas)
First identified in Streptococcus pyogenes, the native type II
CRISPR/Cas system is a bacterial adaptive immune response and
the simplest among the three CRISPR/Cas systems that requires
only four Cas proteins. During exposure to foreign DNA (the
acquisition phase), the type II CRISPR/Cas system incorporates a
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short foreign DNA sequence (protospacer), using Cas1 and Cas2
proteins, into the bacterial genome between short palindromic
repeats, thus forming a CRISPR array. The expression phase
of the immune response occurs when the CRISPR locus is
transcribed into a long non-coding pre-CRISPR RNA (pre-
crRNA), along with its partial complement, the trans-activating
CRISPR RNA (tracrRNA). The tracrRNA forms base pairs with
the repeat sequences of pre-crRNA, and host RNAIII cleaves the
repeat sequence to produce mature crRNAs. For DNA cleavage
to occur (the interference phase), the crRNA:tracrRNA:Cas9
complex scans the invading DNA for the PAM sequence and,
upon Watson-Crick base pairing between crRNA and foreign
DNA, neutralizes it via a DSB (for a review, see Sorek et al., 2008;
Horvath and Barrangou, 2010; Jiang and Doudna, 2015; Wright
et al., 2016).
Since the CRISPR sequence was discovered in 1987 (Ishino
et al., 1987), the utility of CRISPR/Cas for targeted DNA cleavage
was first demonstrated in 2012 in vitro and in bacterial cells
(Gasiunas et al., 2012; Jinek et al., 2012). Unique from ZFNs and
TALENs, which use protein domains to recognize specific DNA
sequences, the CRISPR/Cas system uses RNA-based sequence
recognition (Figure 1A). The crRNA and tracrRNA in the
native system were simplified into a single guide RNA (sgRNA)
of approximately 100 nucleotides with a generic tetraloop
secondary structure to improve ease-of-use and customizability
for engineering (Jinek et al., 2012). Since the application of
CRISPR/Cas systems in mammalian cells (Cho et al., 2013; Cong
et al., 2013; Jinek et al., 2013; Mali et al., 2013b), the technology
has rapidly evolved: multiplexing in the CRISPR/Cas system
(Cong et al., 2013), developing a paired Cas9 nickase system
(Shen et al., 2014), dimerizing the dCas9 (dead Cas9; catalytically
inactive) system fused to FokI endonuclease (Tsai et al., 2014a),
adding a DNA-binding domain for improved target specificity
(Bolukbasi et al., 2015), or splitting Cas9 into two components for
improved packaging and delivery in a viral vector and temporal
control (Truong et al., 2015; Wright et al., 2015; Zetsche et al.,
2015b). Other efforts focus on reducing targeting limitations
posed by the strict PAM recognition sequence. Different variants
of Cas proteins have been shown to reduce targeting limitations
(Kleinstiver et al., 2015); for example, a Cas9 ortholog, Cpf1, uses
a T-rich PAM sequence (Zetsche et al., 2015a).
With these successive innovations, the CRISPR/Cas9 system
has become widely adapted for genome engineering. Some of
the reasons for its popularity are the constructs to produce
sgRNA can be easily prepared with one cloning process, the Cas9
construct can be re-used without any modification, and targeting
multiple loci (multiplexing) is easily achieved by introducing
several sgRNAs. The simplicity of sgRNA production has made it
possible to generate libraries of knockout guide RNAs for either
human ormouse genes that are useful for forward genetic screens
(Koike-Yusa et al., 2013; Shalem et al., 2014).
DNA Double-Strand Break Repair in
Neurons
DNA double-strand breaks (DSBs) induced by targetable
endonucleases are only the first step in mutagenesis (Figure 1B).
The perturbation of the genomic DNA sequence is useful in
genome engineering only because cellular DNA damage signals
and repair machineries are activated and fix the damaged
sequence. It is the repair process that we exploit to isolate desired
disease alleles or to revert mutations to wild-type sequences.
Such DNA repair pathways are rapidly mobilized after
damage because maintaining genomic integrity is critical for cell
survival and function. DNA damage can occur in many ways.
Cell metabolism generates oxidative DNA damage, ultraviolet
radiation results in single- or double-strand breaks, and cross-
linking agents lead to intra- or inter-strand linkages (Lindahl,
1993; Rao, 1993; Brooks, 2002; Caldecott, 2008; McKinnon,
2013; Pan et al., 2014). Among the many forms of DNA
damage, double-strand breaks (DSBs) are considered the
most detrimental and are repaired by three major pathways:
homologous recombination (HR), homology-directed repair
(HDR), and non-homologous end joining (NHEJ) (Figure 1B;
Lieber, 2010; Chiruvella et al., 2013; Jasin and Rothstein, 2013).
The HR pathway allows an error-free repair and requires an
extensive sequence homology from which the sequences of the
damaged DNA can be faithfully copied. The sequence homology
is provided by the sister chromatid, and thus HR is operational
during the S and early G2 phases of the cell cycle during
which the sister chromatid is available (Potter et al., 1987;
Maryon and Carroll, 1991; Benjamin and Little, 1992; Kadyk
and Hartwell, 1992). NHEJ is an error-prone process in which
the broken DNA ends are directly ligated through the end
processing proteins, Ku70:Ku80 [a part of DNA dependent
protein kinase (DNA-PK)], catalytic subunit of DNA-PK (DNA-
PKsc), and ligase IV (Critchlow and Jackson, 1998). During
this end-joining process, small-scale nucleotide insertions and
deletions (indels) are commonly involved (Heidenreich et al.,
2003). Since NHEJ does not require a homology sequence, it
can occur throughout the cell cycle. HDR broadly defines a
wide array of homology-dependent pathways of the DNA repair
including single-strand annealing (SSA) and alternative NHEJ,
also called microhomology-mediated end joining (MMEJ; He
et al., 2015). MMEJ utilizes small homologous sequences (1–25
nt) within either end of the broken DNA (Liang et al., 2008;
McVey and Lee, 2008). Like NHEJ, most HDR processes can
occur throughout the cell cycle. On the basis that both HDR
and HR use homologous sequences, HR can be considered part
of HDR (Lieber, 2010). Yet, HR possesses processes unfound in
HDR or NHEJ, such as extensive processing of the 5′-end of the
DNA lesion and strand invasion by the Rad51-bound 3′-end of
the lesion (Maryon and Carroll, 1991; Shinohara et al., 1992; Van
Dyck et al., 1999; Jasin and Rothstein, 2013). Since DNA repair
is a critical process for cell survival, the various repair pathways
can be activated by different damage signals. Although there are
proteins dedicated to a particular pathway, many of the signaling
and repair molecules are redundant rather than exclusive to a
single pathway (Takata et al., 1998; Madabhushi et al., 2014).
DNA repair pathways are utilized in two distinct phases in
neurons. During the development of an organism, the highly
proliferative neural tissues mainly use HR. At this stage, failure
to faithfully repair the genome leads to apoptosis (Waser et al.,
1979; Sugo et al., 2000; Orii et al., 2006). Since a single error in
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progenitor cells can lead to severe failures in a large number of
cells, either a complete repair or abortive apoptosis is adaptive
for the survival of the organism. Once neurons develop, the
mature neurons are post-mitotic and their DNA is no longer
replicated. In these mature neurons, the sister chromatid with
sequence homology is not available and therefore HR is rare.
NHEJ is considered to be the major pathway for DNA repair
in adult neurons and apoptosis is not promoted (Sonoda et al.,
2006; Fortini and Dogliotti, 2010; Iyama and Wilson, 2013).
Whereas global repair activities are down-regulated in post-
mitotic neurons, transcription-dependent DNA repair pathways
are highly active, and transcribed genes are actively repaired
regardless of the type of DNA damage (e.g., single strand or
double-strand breaks; Nouspikel and Hanawalt, 2000, 2002).
Although there is mounting evidence that connects DNA DSBs
to neurodegeneration (Hochegger et al., 2006; Wang et al.,
2013; Rulten et al., 2014), it is still not clear how these DSBs
lead to neurodegeneration in mature neurons (for a review, see
McKinnon, 2013; Madabhushi et al., 2014). Also uncertain is
whether it is the type or number of errors that contributes to
neurodegeneration.
Recently, it was found that DNADSBs occur as part of normal
neuronal physiology, and these DSBs are closely tied to learning,
memory, and novel experience-dependent synaptic changes
(Suberbielle et al., 2013; Madabhushi et al., 2015). These DSBs
have been demonstrated to be required in the promoter regions
of early-response genes—responsible for memory formation
and synaptic consolidations—in primary neuron culture and
hippocampal slices of Swiss Webster mice, and also in an
in vivo training paradigm for contextual fear conditioning in 6-
month-old mice (Madabhushi et al., 2015). In an exploration of
novel environment learning paradigm, the DSBs in hippocampal
regions in 4-7-month-old mice are repaired within 24 h of the
occurrence (Suberbielle et al., 2013). The pathogenic protein in
Alzheimer’s disease, amyloid-beta, made DSBs persist beyond the
24-h period in 4-7-month-old human amyloid precursor protein
(hAPP) transgenic mice (Suberbielle et al., 2013). In addition,
DSB repair protein BRCA1 is depleted in a mouse model of
Alzheimer’s disease, and the depletion is correlated with cognitive
decline in mice compared to wild-type mice (Suberbielle et al.,
2015). These findings indicate that functional DSB repair is
associated with normal neuronal physiology and impaired DSB
repair with pathophysiology.
The distinctive DNA repair mechanisms and physiologic
utility of DSBs in neurons warrant further investigation on the
consequences of using targetable endonucleases in the nervous
system. The majority of studies on the functions of PDBAs
and the outcomes of PDBA applications were conducted with
dividing cell lines such as immortalized cells (Cermak et al.,
2011; Christian et al., 2012; Garg et al., 2012; Cho et al., 2013;
Cong et al., 2013; Jinek et al., 2013) or stem cells (Hockemeyer
et al., 2011; Cong et al., 2013; Ding et al., 2013a,b; Osborn
et al., 2013; Mali et al., 2013b). The result of PDBA-induced
DSBs is likely to be different in post-mitotic neurons compared
with mitotic cells. For example, a faithful sequence correction
might be more difficult in nervous tissues since the incorporation
of exogenous DNA might be favorably mediated by HDR or
NHEJ, both of which are more error-prone repair processes
than HR. Or, it could be that neurons might activate the HR
pathway if given exogenous DNA templates. These questions
need to be empirically determined. Once detrimental mutations
occur by DSBs, the nervous tissue would be more susceptible to
degeneration since the restoration of the cell population through
cell divisions is unlikely. These considerations need to be taken
into account when targeting PDBAs in the nervous system as
somatic therapeutic agents. Developing an experimental system
with which nervous tissue-specific perturbations can be tested
will be invaluable to spur therapeutic PDBA development
targeting neuronal disorders.
NHEJ: Knock-Outs
Since indels in the NHEJ pathway can lead to frameshift
mutations producing nonfunctional truncated proteins and loss
of protein, NHEJ has been the predominant mode of PDBA-
mediated mutagenesis. In earlier applications of PDBA-mediated
targeted NHEJ in neuroscience, neuronal genes are targeted in
dividing cells to demonstrate that mutations can be introduced
at the target loci. Cong et al. targeted EMX1, Th, and PVALB
implicated in neurodevelopment or neurodegeneration using a
Cas9 system in HEK293FT cells (Cong et al., 2013; Table 1).
PDBA-mediated NHEJ enabled an important advance in rapid
modeling of human diseases in animals and cell lines. With
PDBAs, virtually any genetic make-up with a well-defined genetic
basis (e.g., monogenic) can be produced to model a disease in
terms of genomic sequences, if we set aside for another discussion
the caveats of biologically replicating the phenotypes, genetic
compensation in germline mutants, and embryonic lethality in
essential genes. Several investigations have introduced mutations
to neuronal loci in zebrafish using ZFNs (Schmid et al., 2013),
TALENs (Bedell et al., 2012; Huang et al., 2013), and a Cas9
system (Hwang et al., 2013), in rats using TALENs (Ferguson
et al., 2013), and in mice and rats using a Cas9 system (Li et al.,
2013; Tables 1, 2). PDBA-mediated NHEJ has made it possible to
model neuropsychological and neurodevelopmental disorders in
animals that were previously not possible due to lack of germline
competent embryonic stem cells (ESCs). Using TALENs, two
groups reported successful modification of the MECP2 locus
implicated in Rett syndrome in non-human primate models (Liu
H. et al., 2014; Liu Z. et al., 2014). In these two investigations,
only one group saw successful birth of injected animals (Liu
H. et al., 2014). The fact that the other group could not
maintain the surrogate mother’s pregnancy of injected zygotes
indicates that mosaic F0 animals might not be viable when the
mutagenic efficiency of PDBAs is high. Another group targeted
PPARG—implicated in neurodegeneration—with a Cas9 system
in cynomolgus monkeys (Macaca fascicularis; Niu et al., 2014).
These genetic perturbations have not been fully investigated yet
for their phenotypes, nor the degree to which they model human
diseases. More follow-up investigations are expected in which the
biological relevance of the models to human diseases is reported.
Moving beyond dividing cells and germline mutations in
mutant animals, four groups directly applied Cas9 systems in
post-mitotic neurons in which two synaptic proteins, an NMDA
receptor subunit (Incontro et al., 2014; Straub et al., 2014) and
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TABLE 1 | Neuronal target loci: knock-out.
References Locus* Implication** System Delivery Goal Perturbation Results
Keatinge et al.,
2015
gba1 GD, PD Zebrafish 1-cell embryo
injection of TALEN
mRNA
Germline transmission KO; small indels gba1c.1276_1298del
mutant line
Yao et al.,
2015
Gpr52 HD Mouse Zygote injection of
TALEN mRNA
Germline transmission KO; small indels Indel mutants
Mehrabian
et al., 2014
Prnp Prion diseases,
AD
N2a, C2C12,
NMuMG cells
Cas9 and sgRNA
plasmid
co-transfection
Mutant cell lines KO; small indels Indel mutant lines
Zuris et al.,
2014
EMX1;
Tau-EGFP
Neuronal marker HEK293T;
mESCs
Cationic lipid
transfection of
Cas9:sgRNA
protein:RNA complex
Mutant cell lines KO; small indels Indel mutations;
Loss of GFP signal
Atoh1-GFP;
EMX1
Hair cell marker
in cochlea
Mouse, adult Cochlear injection of
cationic lipid prep of
Cas9:sgRNA
protein:RNA complex
Somatic and local
alteration of genomic
sequence
KO; small indels Loss of GFP
signal; indel
mutations
Swiech et al.,
2014
Mecp2 Rett syndrome Mouse primary
cortical neurons
(E16)
AAV-Cas9 and
AAV-sgRNA vector
co-transduction
Mutant primary cells KO; small indels Indel mutant cells
Mouse, adult Hipp DG injection of
AAV-Cas9 and
AAV-sgRNA vectors
Somatic and local
alteration of genomic
sequence
KO; small indels Indel mutations
Dnmt1, Dnmt3a,
Dnmt3b
Synaptic
plasticity
Mouse, adult Hipp DG injection of
AAV-Cas9 and
AAV-sgRNA vectors;
multiplexing
Somatic and local
alteration of genomic
sequence
KO; small indels Indel mutations
Incontro et al.,
2014
Grin1, Gria2 Synaptic
plasticity and
transmission
Hipp slice or
dissociated
culture of
postnatal rat
Biolistic
co-transfection of
Cas9 and sgRNA
plasmids or lentiviral
vector
co-transduction
Mutant primary cells KO; small indels Indel mutant cells
Straub et al.,
2014
Grin1 Synaptic
plasticity
Mouse Intrauterine
electroporation of
Cas9, sgRNA, and
GFP plasmids
Somatic and local
alteration of genomic
sequence,
– Functional analysis
of KO through
electrophysiology
hipp slice culture
of postnatal rat
Biolistic transfection
(rat) of Cas9, sgRNA,
GFP plasmids
Mutant primary cells – Functional analysis
of KO through
electrophysiology
Ponomareva
et al., 2014
clstn-1 Axon branching,
endosomal
trafficking, AD
Zebrafish 1-cell embryo
injection of TALEN
mRNA
Germline transmission KO; small indels clstn1uw7 mutant
line
Liu H. et al.,
2014
MECP2 Rett syndrome Rhesus and
cynomolgus
monkeys
Zygote injection of
TALEN plasmids
Germline transmission KO; small
indels; SNPs
F0 mosaic
mutants obtained
Richard et al.,
2014
Artificial
trinucleotide
repeats
Neurodegeneration Yeast TALEN plasmid
transformation in
yeast strains
Yeast cells with
sequence alterations
KO; deletions Trinucleotide
contraction
Liu Z. et al.,
2014
MECP2 Rett syndrome Cynomolgus
monkeys
Zygote injection of
TALEN mRNA
Germline transmission KO; small indels A F0 mosaic
mutant stillborn
(Continued)
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TABLE 1 | Continued
References Locus* Implication** System Delivery Goal Perturbation Results
Niu et al.,
2014***
PPARG MS, AD, PD,
ALS, and glioma
Cynomolgus
monkeys
Zygote injection of
Cas9 mRNA and
sgRNAs; multiplexing
Germline transmission KO; small indels F0 mosaic
mutants obtained
Huang et al.,
2013
Tandem repeats
[(TG)n]
Fragile X
syndrome, HD,
Friedreich’s
ataxia
Zebrafish 1-cell embryo
injection of TALEN
mRNA
Somatic mutants;
mosaic animals
KO; deletions Length change in
(TG)n
Ferguson
et al., 2013
Tlr4 Ethanol-induced
neuroinflammation
and behavioral
effects
Rat Zygote injection of
TALEN mRNA
Germline transmission KO; indels Tlr413del mutants
Li et al., 2013 Th, Rheb, Mc4r Dystonia, TSC,
BN
Mouse, rat Zygote injection of
sgRNA and Cas9
plasmid or RNA
Germline transmission KO; indels Indel mutants
Schmid et al.,
2013
tardbp, tardbpl ALS, FTLD-TDP Zebrafish Zygote injection of
ZFN mRNA
Germline transmission KO; indels tardbp−/− or
tardbpl−/−
mutants
Cong et al.,
2013
EMX1, TH,
PVALB
Neurodev,
dystonia, SCA1
HEK293FT Cas9 and sgRNA
plasmids
co-transfection
Mutant cell lines KO; indels Indel mutants
Hwang et al.,
2013
apoea, gria3a,
th1, rgs4,
slc6a3, drd3
AD, ID,
schizophrenia,
OCPD
Zebrafish 1-cell embryo
injection of Cas9 and
sgRNA plasmids
Germline transmission KO; indels Indel mutants
Programmable DNA-binding agents (PDBAs; ZF, TALE, and Cas systems) are applied to knock-out target genes.
*Loci: APOE, apolipoprotein E; clstn1, calsyntenin 1, zebrafish homolog of human CLSTN1; Dnmts, family of DNA methyltransferases; DRD3, dopamine receptor D3; EMX1, empty
spiracle homeobox 1; gba1, glucocerebrosidase 1, zebrafish orthologue of human GBA1; GFP, green fluorescence protein reporter; Gpr52, G protein-coupled receptor 52, mouse
homolog of human GPR52; Gria2, glutamate ionotropic receptor α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type subunit 2, rat homolog of human GRIA2; GRIA3,
glutamate receptor ionotropic AMPA subunit 3; Grin1, glutamate ionotropic receptor N-Methyl D-Aspartate (NMDA) type subunit 1, rat homolog of human GRIN1; Mc4r, melanocortin
receptor type 4, rat homolog of human MC4R; Mecp2, methyl-CpG binding protein 2 gene, mouse homolog of human MECP2; Prnp, prion protein gene, mouse homolog of human
PRNP; PVALB, parvalbumin gene; RGS4, regulator of G protein signaling 4; Th, tyrosine hydroxylase, mouse homolog of human TH; Rheb, ras homolog enriched in brain, mouse
homolog of human RHEB; tardbp, transactive response DNA binding protein 43 kDa (TDP-43), zebrafish homolog of TDP-43, tardbpl, TDP-43 like; Tlr4, toll-like receptor 4, rat homolog
of human TLR4. There are about 40 more studies that targeted neuronal loci that we could not discuss in this review.
** Implication: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; BN, bulimia nervosa; FTD, frontotemporal dementia; FTLD-TDP, frontotempmoral lobar degeneration with
TDP-43 inclusions; GD, Gaucher’s disease; glioma, neoplasm in the central nervous system; HD, Huntington’s disease; ID, intellectual disability; Neurodev, neurodevelopment; PD,
Parkinson’s disease; SCA1, spinocerebellar ataxia type 1; TSC, tuberose sclerosis.
***Two other non-neuronal loci are also targeted along with PPARG in this study.
C2C12, mouse myoblast cell line; Cas, CRISPR-associated; DG, dentate gyrus; ESCs, embryonic stem cells; F0, PDBA-injected generation; HEK293, human embryonic kidney cell
derivative line; hESCs, human ESCs; indels, insertion and deletion mutations; Hipp, hippocampus; HSV, herpes simplex virus; herpes simplex viral vector; iPSCs, induced pluripotent
stem cells; KI, knock-in; KO, knock-out; mESCs, mouse embryonic stem cells; N2a, mouse Neuro 2a cell line derived from neuroblastoma; NMuMG, mouse mammary gland epithelial
cell line; NSCs, neural stem cells; sgRNA, single guide RNA; TALENs, transcription activator-like effector nucleases; ZF, zinc finger; ZFN, zinc finger nuclease.
an AMPA receptor subunit (Incontro et al., 2014), are targeted
(Table 1). Straub et al. locally altered the genomic sequence in a
Grin1 locus (NMDA receptor subunit 1) in vivo in E15 mouse
hippocampi by delivering Cas9 and sgRNA plasmids through
in-utero electroporation, as well as in hippocampal slice culture
through biolistic transfection (Straub et al., 2014). The resulting
neurons showed altered electrophysiological profiles providing
functional evidence that the target gene, Grin1, is knocked
down. However, mutations were not directly sequenced. Incontro
et al. knocked out either Grin1 or Gria2 (AMPA subunit 2) in
hippocampal slice culture from 6 to 11-day-old rats by delivering
Cas9 and sgRNA plasmids through biolistic transfection (14-day
expression of the construct before electrophysiology; Incontro
et al., 2014). Incontro et al. showed that electrophysiological
profiles were altered in the knock-out cells. They also reported
that >90% of the mutations in Grin1 had indel mutations that
were out-of-frame and that the function of the target protein was
100% altered in all cells in which Cas9 expression was confirmed
(Incontro et al., 2014). The findings by Incontro et al. imply
that NHEJ could be the dominant mode of DNA DSB repair in
post-mitotic neurons and that mutagenesis in neural cells could
be much higher compared to other somatic cells because their
post-mitotic nature does not allow the dilution of PDBAs.
Similarly, Swiech et al. targeted Mecp2 or DNA
methyltransferases (Dnmt1, Dnmt3a, and Dnmt3b; via
multiplexing) in post-mitotic neurons in vitro and in vivo
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TABLE 2 | Neuronal target loci: knock-in.
Refernces Locus* Implication** System Delivery Goal Perturbation Results
Wen et al.,
2016
DISC1 Schizophrenia iPSCs, forebrain
neurons
TALEN and donor
plasmid co-transfection
in iPSCs
WT or mutant
cell lines
KI; correction or
introduction of patient
mutation
DISC1WT or
DISC14bp-del
Lenzi et al.,
2015
FUS ALS iPSCs, spinal
motoneurons
TALEN and donor
plasmid co-transfection
Mutant cell
lines
KI; codon
replacement
FUSP525L mutant
iPSCs and neurons
Vannocci
et al., 2015
FXN Friedreich’s
ataxia
HEK293 Donor and TALEN or
Cas9/sgRNA plasmid
co-transfection
Mutant cell
lines
KI; Introduction of
donor sequence
Inducible FXN
mutants
Kiskinis et al.,
2014
SOD1 ALS iPSCs, spinal
motoneurons
ZFN and donor plasmid
co-transfection in
iPSCs
Mutant cell
lines
KI; correction of
patient mutation
SOD1A4V →
SOD1WT
Wainger
et al., 2014
SOD1 ALS Same method as
Kiskinis et al., 2014
– – – –
Chen et al.,
2014
SOD1 ALS iPSCs, spinal
motoneurons
TALEN and donor
plasmid co-transfection
in iPSCs
Mutant cell
lines
KI; correction of
patient mutation
SOD1D90A →
SODWT
Sanders
et al., 2014
LRRK2 PD iPSCs,
dopaminergic
neurons
ZFN and donor
co-transfection in
iPSCs (method not
disclosed, proprietary
information)
WT cell line KI; correction of
patient mutation
LRRK2G2019S →
LRRK2G2019S
An et al.,
2014
HTT HD HEK293, iPSCs Cas9 WT, Cas9
nickase, or TALEN and
donor plasmid
co-transfection
Mutant cell
lines
KI; introduction of
mutation
HTT97Q
Jones and
Meisler, 2014
Scn8a Epileptic
encephalopathy
Mouse Zygote injection of
TALEN mRNA and
donor plasmid
Germline
transmission
KI; introduction of
mutation
Scn8aN1768D mutant
Hruscha
et al., 2013
tardbp,
tardbpl,
C13H9orf72
ALS, FTD Zebrafish 1-cell embryo injection
of Cas9 mRNA and
sgRNA
Germline
transmission
KO; small indels Indel mutants
tardbp,
C13H9orf72
ALS, FTD Zebrafish 1-cell embryo injection
of Cas9 mRNA,
sgRNA, and ssODNs
Germline
transmission
KI; introduction of HA
tag
HA tag insertion
Woodruff
et al., 2013
PSEN1 AD iPSCs, neurons TALEN plasmid and
ssODN co-transfection
Mutant cell
lines
KI; introduction of
patient mutation
PSEN1Exon9skip
Panda et al.,
2013
FUS ALS Mouse Zygote injection to
pronuclei of TALEN
mRNA and ssODNs
Germline
transmission
KI; codon
replacement
FUSR513G or
FUSP517L mutant
3110043021Rik ALS (C9orf72) Mouse Zygote injection to
pronuclei of TALEN
mRNA
Germline
transmission
KO; small indels Indel mutants
Fong et al.,
2013
MAPT Tauopathy iPSCs,
dopaminergic,
glutamatergic, or
GABAergic neurons
ZFN and donor plasmid
co-transfection in
iPSCs
Mutant cell
lines
KI; correction or
introduction of patient
mutation
MAPTA152T/A152T or
MAPTWT/WT
Zu et al.,
2013
th Dystonia Zebrafish 1-cell embryo injection
of TALEN mRNA and
donor plasmids
Germline
transmission
KI; introduction of
reporter (EGFP)
EGFP insertional
mutants
(Continued)
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TABLE 2 | Continued
Refernces Locus* Implication** System Delivery Goal Perturbation Results
Bedell et al.,
2012
crhr1 HPA axis
modulation,
anxiety
Zebrafish 1-cell embryo injection
of TALEN mRNA
Germline
transmission
KO; small indels Indel mutants
crhr2 Eating disorder 1-cell embryo injection
of TALEN mRNA and
ssODN
Germline
transmission
KI; introduction of
LoxP sequence
Mutants
Soldner et al.,
2011
SNCA PD hESCs, iPSCs ZFN and donor plasmid
co-transfection
Mutant or WT
cell lines
KI; introduction or
correction of patient
mutation
SNCAA53T,
SNCAE46K mutant,
SNCAWT
Programmable DNA-binding agents (PDBAs; ZF, TALE, and Cas systems) are applied to knock-in exogenous sequences at target loci.
*Loci: 3110043021Rik, mouse homolog of the human C9orf72; C9orf72, chromosome 9 open reading frame 72; C13H9orf72, zebrafish homolog of the human C9orf72; DISC1,
disrupted in schizophrenia 1; FUS, fused in sarcoma/translocated in liposarcoma; FXN, frataxin; HTT, huntingtin; MAPT, microtubule-associated protein Tau; MECP2, methyl-CpG
binding protein 2 gene; PPARG, peroxisome proliferator-activated receptor gamma; Scn8a, sodium channel, voltage-gated, type VIII, alpha subunit; SNCA, alpha-synuclein, non A4
component of amyloid precursor; SOD1, superoxide dismutase 1; tardbp, transactive response DNA binding protein 43 kDa (TDP-43), zebrafish homolog of TDP-43; tardbpl, TDP-43
like; th, tyrosine hydroxylase, zebrafish homolog of human TH.
** Implication: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; glioma, neoplasm in the central nervous system; HD, Huntington’s disease;
PD, Parkinson’s disease.
Cas, CRISPR-associated; ESCs, embryonic stem cells; F0, PDBA-injected generation; hESCs, human ESCs; HSV, herpes simplex virus; herpes simplex viral vector; indels, insertion
and deletion mutations; iPSCs, induced pluripotent stem cells; KI, knock-in; KO, knock-out; sgRNA, single guide RNA; ssODNs, single strand oligodeoxyribonucleotides; TALENs,
transcription activator-like effector nucleases; ZF, zinc finger; ZFN, zinc finger nuclease.
by stereotactically delivering Cas9 and sgRNA in adeno-
associated viral vectors to the hippocampal dentate gyrus in adult
mice (Swiech et al., 2014; Table 1). In primary cortical neuron
culture, ∼70% of transduced cells showed knock-out of Mecp2
by immunocytochemistry, western blot, and next generation
sequencing. The in vivo knock-out efficiency was ∼68%
in purified nuclei of transduced cells (in vivo transduction
efficiency of the vector was ∼80%) from dissected brain tissue.
TheMecp2 mutations led to altered performance in a contextual
fear-conditioning paradigm, reinforcing that the in vivo
knockdown of Mecp2 in hippocampal cells has neuronal and
behavioral consequences. Swiech et al. also demonstrated that
somaticMecp2 knockdown affects the functions of neural circuits
by showing altered primary visual cortex (V1) function when
Mecp2 was targeted in the superficial layers of V1. Multiplexed
targeting in vivo created mutations in Dnmt3a, Dnmt1, and
Dnmt3b loci with ∼75, ∼75, and ∼50% indel rates, respectively,
when the three loci were targeted in a single transduction in the
hippocampus (Incontro et al., 2014). Swiech et al. demonstrated
that Cas9-mediated multiplexed gene targeting in the nervous
system can be accomplished in vitro, in vivo, and in localized
somatic application as well as through zygotic injections. Most
recently, Zuris et al. demonstrated non-viral delivery of PDBAs
in in vitro and in vivo post-mitotic neuronal cells (Zuris et al.,
2014; Table 1). Zuris et al. delivered a Cas9:sgRNA protein:RNA
complex in cationic lipid to the cochlear and altered the EMX1
locus with ∼20% efficiency in neuronal cells (the outer hair
cell) in 1-day-old mice. These four cases represent diverse Cas9
systems delivered with DNA plasmids, viral vectors, or cationic
lipids, which are directly applicable to post-mitotic neurons
in vitro and in vivo. These work demonstrate the feasibility of
neuronal genome engineering and provide evidence that the
mutagenic efficiency is comparable to or higher than that in
dividing cells.
In addition to neuronal applications of PDBA-mediated
NHEJ, understanding and exploiting the properties of NHEJ are
underway in many investigations. Beyond out-of-frame knock-
outs, in-frame indel mutations also occur and may be useful to
study the function of specific amino acid residues or putative
protein domains (Sung et al., 2013). Microhomology-mediated
end joining (MMEJ) often results in deletions or translocations
(He et al., 2015). First shown in mammalian cells in 1986, MMEJ
has become a useful tool to bias deletions toward frameshift
mutations (Roth and Wilson, 1986). The property of MMEJ that
allows researchers to better predict mutagenic outcomes might
be particularly useful for neuroscientists since NHEJ–resulting
in random mutations–appears to be more active compared to
dividing cells. Several software options provide microhomology-
based prediction functions to design TALENs and CRISPR/Cas9
gRNAs that are more likely to induce frameshift mutations (Neff
et al., 2013; Bae et al., 2014a).
HDR and HR: Knock-Ins
Unlike the NHEJ repair pathway, HR and some versions of
HDR utilize an external DNA donor and repair the DNA
damage without introducing erroneous sequences. A single-
stranded oligo with short sequence homology (∼50 nt) to the
genomic DNA can act as a template for HDR, and a donor DNA
construct with extended homology arms (hundreds to thousands
of bps) can act as a template in HR. Applications of PDBA-
mediated knock-ins in neuroscience have focused on engineering
induced pluripotent stem cells (iPSCs) and generating animal
models (Table 2). First, it has been a widely-used and effective
approach to engineer patient-derived iPSCs with PDBAs to
revert a disease-causing allele to wild-type via HDR and to
differentiate these engineered and control (without modification)
iPSCs to neurons. The genome engineered iPSCs and neurons
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are identical to the patients’ cells except the corrected DNA
sequences and a certain level of single nucleotide polymorphisms
(SNPs) inherent to all stem cell models. Patient-derived iPSCs
have been used to investigate altered cellular functions and
establish cell-autonomous disease models in Parkinson’s disease
(PD), tauopathy, amyotrophic lateral sclerosis (ALS), Alzheimer’s
disease, andHuntington’s disease (HD) using ZFN (Soldner et al.,
2011; Fong et al., 2013; Kiskinis et al., 2014; Sanders et al., 2014),
TALEN (Woodruff et al., 2013; Chen et al., 2014; Lenzi et al.,
2015; Wen et al., 2016), and Cas9 systems (An et al., 2014;
Table 2).
Whereas a knock-in approach had been challenging and
time-consuming in animal models, PDBAs have spurred the
generation of knock-in cell and animal models based on
increased efficiencies of HR. When considering the rates of
classic HR to be ∼1 × 10−3 and 1 × 10−6 (Smithies et al.,
1985; Thomas and Capecchi, 1986; Puchta et al., 1993; Rouet
et al., 1994; Choulika et al., 1995; Rong and Golic, 2001), PDBAs
can increase donor sequence integration at a rate of ∼1–45%
by generating DSBs in the genomic target locus (Urnov et al.,
2005; Beumer et al., 2008; Greenwald et al., 2010; Li et al., 2013;
Zu et al., 2013; Gratz et al., 2014; Krentz et al., 2014; Platt
et al., 2014; Shin et al., 2014a; Xie F. et al., 2014a; Karakikes
et al., 2015; Lee et al., 2015; Wang et al., 2016). Although direct
comparison is nearly impossible because of the differences in
the knock-in system, including the size and design of the donor,
selection systems, and target loci in the genome, targeted DSBs
with PDBAs are viewed as improving HR rates by 3–6 orders of
magnitude. Bedell et al. first showed in vivo knock-in of modified
LoxP sequences in a neuronal locus, crhr2, by zygote injection of
TALENmRNA and a single-stranded oligonucleotide in zebrafish
(Bedell et al., 2012; Table 2). Currently, patient allelic variants of
many neuronal disorders have been introduced and modeled in
mice and zebrafish using TALEN (Panda et al., 2013; Jones and
Meisler, 2014) and Cas9 systems (Hruscha et al., 2013) ranging
from epilepsy to schizophrenia (Table 2).
Directly knocking-in exogenous DNA sequences with PDBAs
in post-mitotic neurons has not been reported to our knowledge.
It will be an important area of investigation when developing
therapeutics, and the mechanism of foreign DNA knock-in
is being pursued to improve future therapeutic applications.
It is important to recognize that the NHEJ, HDR, or HR
pathways all can be used to introduce exogenous DNA sequences
into the genome. A linear piece of double-stranded DNA
may be incorporated into the genome even during NHEJ
repair (Lin and Waldman, 2001; Miller et al., 2004; Gabriel
et al., 2011). This NHEJ process is still prone to errors at
the break site and the mechanism is unclear. Inactivating key
components of the NHEJ pathway (e.g., ligase IV) has been
demonstrated to bias DSB repair away from NHEJ, in one
example increasing HR efficiency by 20–65% in Drosophila
(Beumer et al., 2008). Another way to circumvent the NHEJ
pathway is by generating single-strand overhangs with nickases
and providing a double-stranded oligo with complementary
overhangs on either side (Ran et al., 2013). Albeit with lower
efficiency, HR-based knock-ins with short or long homology
arms allow many experimental manipulations—including the
introduction of promoters, reporters, recombination sites,
and wild-type alleles—with high accuracy and are utilized
in neuroscience research (Liu et al., 2011; Corti et al.,
2012).
EPIGENETIC MODIFICATION AND
TRANSCRIPTIONAL CONTROL
There are estimated to be hundreds to thousands of types of
neuronal cell populations (Stevens, 1998; Shin et al., 2014b) in
the mammalian cortex, suggesting equally complex epigenetics
in the nervous system. Development, physiological function
(such as memory consolidation), and pathological changes in
neuropsychiatric and neurodegenerative disorders are closely
tied to epigenetic changes (for a review, see Tsankova et al., 2007;
Morris and Monteggia, 2014; Reul, 2014). In recent years, we
have significantly broadened our understanding of the three-
dimensional structures and organizations of chromatin in the
nucleus (Takizawa and Meshorer, 2008; Lieberman-Aiden et al.,
2009; Phillips-Cremins et al., 2013; Rao et al., 2014). Similar
to how the deluge of genomic sequencing data has urged the
functional study of disease-associated and candidate genes, we
are in need of functional understanding of higher chromatin
structures and their connection to neuronal diseases. The ability
to perturb epigenetic states, gene expression patterns, and higher
order chromatin structures in a targeted manner has been
largely unavailable. Although it is still at a fledging state, we
will discuss multiple investigations that have reported success
in direct modulation of gene expression, epigenetic modulation,
building synthetic circuits, and modifying regulatory elements
in mammalian cells, yeasts, and prokaryotes using PDBAs. The
majority of the studies were conducted in dividing cells, and only
a small portion of the studies targeted neuronal loci. Still, these
early studies demonstrate the feasibility of controlling regulatory
elements with PDBAs and are worth a discussion for their future
adoption in the nervous system.
Regulation of Gene Expression
As the name implies, TALEs were first identified and adapted
as transcription factors (Bai et al., 2000; Gu et al., 2005; Boch
et al., 2009; Moscou and Bogdanove, 2009). Applying this
inherent functionality, TALEs have been used to up-regulate the
expression of specific genes at targeted loci (Zhang et al., 2011;
Figure 2A). The application of single TALEs showed a moderate
effect of two to five-fold increases in target gene expression in
endogenous loci (SOX2, KLF4) in HEK293T cells, but the fold
increase could be augmented from 50- to 10,000-fold by applying
multiple TALEs targeting an endogenous promoter (Perez-
Pinera et al., 2013b; Maeder et al., 2013c). Replacing the TALE’s
native activation domain with a stronger activation domain
(VP16 and later VP64) increased activation by 10 times in a
reporter system (Geiβler et al., 2011). In addition, TALEs have
been shown to repress gene expression when fused to a repressor
domain such as the EAR-repression domain (SRDX) in plants
(Mahfouz et al., 2011) and the Krüppel-associated box (KRAB)
or Mad interaction domain (SID) in human cells (Cong et al.,
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FIGURE 2 | Modulation of gene expression. Targetable TALE and dCas9 fused to various effector domains modulate gene expression at the target locus in the
genome. Effector domains can be transcription activator domains (e.g., VP64) or repressor domains (e.g., KRAB). A TALE monomer/sgRNA or multiple
TALEs/sgRNAs are targeted to a locus for a range of gene expression modulation. (A) An effector domain is fused to the C-terminus of a TALE. (B) An effector domain
is fused to or interacts with either dCas9 protein or sgRNA. TALE, transcription activator-like effector; dCas9, dead Cas9; catalytically inactivated Cas9 nuclease;
sgRNA, single guide RNA; VP64, tetrameric repeat of herpes simplex virus activation domain (VP16); KRAB, Krüppel-associated box repression domain.
2012). Yet, the modulatory effects of TALEs are inconsistent.
Some TALEs show a higher activity while some fail to modulate
the transcription of the target locus. Although this ineffectiveness
was attributed to repressed regions of chromatin (Zhang et al.,
2011; Bultmann et al., 2012), other studies showed that TALEs
can activate transcription even in repressed chromatin regions
(Scott et al., 2014b). One explanation for this discrepancy is
the location of the TALE binding site in relation to nucleosome
binding. In particular, the activity of TALEs was higher when
targeting DNA sequences that are accessible in the nucleosome,
while not as efficient when targeted to sites covered by the dyad
of the nucleosomes (Scott et al., 2014a). Three studies using
TALENs reported modulation of gene expression in neuronal
loci (Table 3). Cong et al. showed ∼5- and three-fold up-
regulation of mRNA in CACNA1C target loci 1 and 2 with TALE-
VP64 in HEK293FT cells (Cong et al., 2012). Targeting NTF3
in HEK293 cells, Miller et al. reported a ∼30-fold increase in
mRNA expression with TALE-VP16 (Miller et al., 2011) whereas
Maeder et al. saw only a modest increase in the same gene with
TALE-VP64 (though significant; Maeder et al., 2013c). These
two cases show that, even in the same locus, the efficacy of
TALE-mediated gene expression may be affected by multiple
variables such as target loci, design and concentrations of TALE
constructs, cell types, delivery methods, and the genetic make-up
of transfected cells or injected animals. Similarly, different types
of neurons in varying animal models could respond differently to
the application of TALEs.
Although it is useful to be able to modulate gene expression
levels at target loci by simply introducing TALEs to the system,
these applications act constitutively and lack spatiotemporal
control. Inducible TALEs and TALEs with regulated expression
systems were developed to provide further spatiotemporal
control. Allowing for increased temporal regulation, TALEs
bound to a ligand-binding domain could modulate gene
expression in response to light (Konermann et al., 2013),
endogenous signals (Li et al., 2012), or exogenous ligands (Mercer
et al., 2014). The study by Konermann et al. is noteworthy
since the authors not only modulated two neuronal targets in
an inducible system in dividing cells, primary neuron culture,
and in vivo, but also profiled a total of 28 TALE-VP64 systems
in primary neuron culture, each of which individually targeted
one locus (Konermann et al., 2013). Konermann et al. built a
two-hybrid system that allows TALE-mediated gene activation
only when blue light (466 nm) is applied. One component of
the two-hybrid is a TALE monomer bound to cryptochrome 2
protein (CRY2) effector domain that is sensitive to light and the
other comprises a CRY2’s interacting partner (C1B1 protein),
nuclear localization signal, and VP64. With light stimulation,
Neurog2 mRNA is significantly increased from 30min onward
until about 3 h after stopping the stimulation in N2a cells
(mouse neuroblastoma cell line), reaching a peak induction of
20-fold compared to that of unstimulated cells. After AAV-
mediated delivery of inducible constructs targeting a Grm2 locus
in mouse primary cortical neurons and mice, Konermann et al.
observed ∼four- to six-fold increase in Grm2 mRNA after light
stimulation in neuronal culture and ∼3.5-fold increase in vivo
(Table 3). In a light-inducible repressor system, Konermann et al.
fused CRY2 with mSin3 interacting domains that repress gene
expression through histone deacetylation and observed two-fold
reduction in Grm2mRNA expression in primary neuron culture
(Konermann et al., 2013). Non-inducible TALE-VP64 constructs
were tested in neurons as well by individually targeting 28
neuronal loci with a significant fold increase ranging from ∼1.5
(Grin2a) to∼33 (Slc6a4).
To generate controlled and coordinated gene circuits, TALEs
that interact with regulatory elements were developed, including
TALEs that control synthetic promoters or TALEs that are
expressed under the control of an artificial regulatory element.
Multiple synthetic promoters that contain a TALE-binding site
simultaneously activated gene expression in multiple loci in
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TABLE 3 | Neuronal target loci: gene expression.
References Locus* Implication** System Delivery Goal Perturbation Results
Amin et al.,
2015
miR-218-1;
miR-218-2***
Motoneuron
disease
Mouse Zygote injection of Cas9
mRNA and two sgRNAs
Germline transmission KO; deletion miR-218-
1370bp-del or
miR-218-
2290bp-del
mutant
Zuris et al.,
2014
NTF3 Neurode
generation
HEK293T Cationic lipid transfection of
(-30)GFP-TALE-VP64
protein or
dCas9-VP64:sgRNA
protein:RNA complex
Transient alteration of
gene expression
– Increased gene
expression
Heller et al.,
2014
Fosb Addiction,
depression
Mouse (juvenile
7-8 wks old)
HSV transduction of
ZF+effector (p65 or G9a)
plasmids
Transient and local
alteration of gene
expression
Acetylation or
methylation of
promoter
Up or
down-regulation of
gene expression
HSV transduction of
TALE+effector (VP64)
plasmids
Transient and local
alteration of gene
expression
– Increased gene
expression
Konermann
et al., 2013
Neurog2,
Grm2+ 27 other
neuronal genes
Neural
differentiation,
PD,
Schizophrenia
N2a, mouse
primary cortical
neurons, mouse
Transfection of
light-inducible TALE
plasmids; transduction of
light inducible AAV-TALE
vectors
Light-induced transient
alteration of gene
expression
– Increased gene
expression with an
improved temporal
control
Maeder et al.,
2013b
NTF3 Neurode
generation
HEK293 dCas9-VP64 and sgRNA
plasmid co-transfection
Transient alteration of
gene expression
– Increased gene
expression
Chapdelaine
et al., 2013
FXN Friedreich’s
ataxia
Human and
mouse fibroblast
TALE-VP64 plasmid
transfection
Transient alteration of
gene expression
– Increased gene
expression
Maeder et al.,
2013c
NTF3 Neurode
generation
HEK293 TALE-VP64 or TALE-p65
plasmid transfection
Transient alteration of
gene expression
– Increased gene
expression
Garriga-Canut
et al., 2012
HTT HD STHdh cells,
mouse
ZFP plasmid or AAV2/1
vector transfection;
Transient or stable
alteration of gene
expression
– Decreased gene
expression
Cong et al.,
2012
CACNA1C Autism HEK293FT TALE-VP64 plasmid
transfection
Transient alteration of
gene expression
– Increased gene
expression
Miller et al.,
2011
NTF3 Neurode
generation
HEK293 TALE-VP64 plasmid
transfection
Transient alteration of
gene expression
– Increased gene
expression
Laganiere
et al., 2010
GDNF PD Human, monkey,
and rat cells
Lentiviral transduction of
ZF-p65
Alteration of gene
expression
– Increased gene
expression
Rat AAV2 transduction of
ZF-p65
–
Programmable DNA-binding agents (PDBAs; ZF, TALE, and RAN-guided Cas systems) are applied to modulate target gene expression.
*Loci: CACNA1C, calcium channel voltage-dependent L-type alpha 1C subunit; Gdnf, glial cell line-derived neurotrophic factor, rat homolog of human GDNF; Grm2, glutamate receptor
metabotropic 2, mouse homolog of human GRM2; HTT, huntingtin; miR-218-1, miR-218-2, microRNA-218 mammalian paralog 1, 2; Neurog2, neurogenin 2, mouse homolog of human
NEUROG2; NTF3, neurotrophin 3.
** Implication: HD, Huntington’s disease; PD, Parkinson’s disease.
***miR-218 and miR-218-2 are knocked out through deletion (370 bp, 290bp). This study by Amin et al. is included in gene expression modulation section because the indels in the
regulatory elements mainly concern gene expression patterns.
(-30)GFP-TALE-VP64, engineered GFP protein with electrostatic charge of -30 fused to TALE-VP64; AAV2, adeno-associated virus type 2; Cas, CRISPR-associated; dCas, dead Cas;
enzymatically inactive; G9a, histone methyltransferase, encoded by EHMT2, euchromatic histone-lysine N-methyltransferase 2; HA tag, human influenza hemagglutinin amino acids 98–
106 epitope tag; HEK293, human embryonic kidney cell derivative line; HSV, herpes simplex virus; herpes simplex viral vector; indels, insertion and deletion mutations; KO, knock-out;
N2a, mouse Neuro 2a cell line derived from neuroblastoma; p65, NF-κB activation domain; sgRNA, single guide RNA; STHdh, neuronal progenitor cell line from mouse embryonic day
14 striatal primordial, first exon of the mouse Htt gene has been replaced by a human HTT exon with 111 CAG repeats; TALE, transcription activator-like effector; TALENs, transcription
activator-like effector nucleases; VP64, tetrameric repeat of herpes simplex virus activation domain (VP16); ZF, zinc finger; ZFN, zinc finger nuclease.
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plants (Brückner et al., 2015), which showed the potential for
a coordinated control of multiple genes. A similar system was
developed to allow for a temporal regulation of TALE expression
and circuit-level control of multiple genes in prokaryotes (Rai
et al., 2015). RiboTALEs incorporate riboswitches upstream of
the TALE-encoding sequences to regulate the time at which
TALEs are expressed. Once expressed, TALEs repress gene
expression of target loci that are engineered to have a TALE-
binding site (Rai et al., 2015). Improved spatiotemporal control
was also demonstrated in mammalian cells by combining the
well-established tetracycline-response element (TRE) and Gal4-
UAS system with TALEs fused to a repressor domain (Li Y.
et al., 2015). Combining a TALE-repressor with other regulatory
systems—in this case, TRE and Gal4-UAS—produced a synthetic
circuit via a two-hybrid regulatory system.
Similar modulations of gene expression were achieved by
engineered CRISPR/Cas systems. Unlike TALEs, the innate
function of the CRISPR/Cas system is to make DNA DSBs
as a bacterial adaptive immune system in nature (Barrangou
et al., 2007; Garneau et al., 2010). To co-opt the CRISPR/Cas
system as a transcription factor system, the innate endonuclease
function of Cas9 is catalytically inactivated (dCas9; dead Cas9)
by introducing D10A and H841A mutations within the nuclease
domains, RuvC1 and HNH, respectively (Jinek et al., 2012;
Figure 2B). The resulting dCas9 without any fused effector
domains tends to block transcription in endogenous loci in
prokaryotes and a reporter system in human cells, presumably
through steric hindrance to the binding or elongation of the RNA
polymerase (RNAP; Qi et al., 2013). dCas9 fused to a repression
domain (KRAB) effectively silenced gene expression both in
endogenous loci (CD71 and CXCR4) and in a reporter system.
When fused to an activating domain (VP64), dCas9 increased
GFP expressions in a reporter system (Gilbert et al., 2013). It was
not reported if there was an activation in an endogenous locus
(Gilbert et al., 2013). A neuronal endogenous locus was targeted
with a dCas9-VP64 system showing a moderate (significant) level
of increase in NTF3 mRNA (∼three-fold) at a concentration of
200 ng sgRNA and 250 ng dCAs9-VP64 and a high increase
(∼5–25) at a concentration of 500 ng sgRNA and 500 ng dCas9-
VP64 (Maeder et al., 2013b). This study indicates that applying
an optimal concentration without toxicity is an important factor.
Robust activation of endogenous gene expression (ranging from
8- to 2000-fold) in human cells (Cheng et al., 2013; Maeder
et al., 2013b; Mali et al., 2013a; Perez-Pinera et al., 2013a) and
in mouse zygotes (Cheng et al., 2013) was later reported, yet a
combination of multiple sgRNAs for each locus was necessary
to see effective activation of the target gene in all studies. Mali
et al. engineered sgRNA to include MS2 bacteriophage coat
protein-binding RNA stem loop at the 3′ end and function as a
effector carrying molecule (Mali et al., 2013a). This approach still
requiredmultiple sgRNAs to significantly activate an endogenous
gene. This is consistent with reports thatmultiple TALEs function
better at increasing the transcription of target locus from two- to
five-fold of a single TALE to 50- to 10,000-fold inmultiple TALEs.
The inability of the CRISPR/dCas9 system to activate
gene expression with one sgRNA was recently amended with
an alternative approach. Instead of linking effector domains
to dCas9, two groups independently engineered the sgRNA
secondary structure allowing the binding of effector domains
to an sgRNA motif similar to the approach by Mali et al.
(Figure 2B). Zalatan et al. incorporated viral RNA sequences of
MS2, PP7, and com into sgRNA (this RNA guide is referred to as
scaffold RNA; scRNA) that are recognized by the MCP, PCP, and
Com RNA-binding proteins, respectively (Zalatan et al., 2015).
The MCP, PCP, and Com proteins are fused to an activation
(VP64) or repression (KRAB) domain and operate as an RNA-
binding adaptor for the effector. This system expanded the two-
factor system of sgRNA and dCas9 to a three-factor system of
scRNA, dCas9, and adaptor-effector. Utilizing this system, each
scRNA activated or repressed a different target locus mediated
by different combinations of the adaptor and effector complex,
maximizing the orthogonal control of gene regulation (Zalatan
et al., 2015). Konermann et al. engineered sgRNA to incorporate
dimerized MS2-binding sequences, made an adaptor-effector
complex comprising MS2-p65-HSF1, and kept the fused VP64
activation domain on dCas9 (this system is currently referred
to as a synergistic activation mediator; SAM; Konermann et al.,
2015). Each group showed that one gRNA-mediated targeting
could increase gene expression in endogenous loci from ∼5-
fold (Zalatan et al.) to ∼15-fold (Konerman et al.). Zalatan
et al. demonstrated orthogonal regulation by simultaneously
activating and silencing gene expression, and Konerman et al.
introduced an optimized system in activating gene expression.
Besides immortalized human cell lines, the CRISPR/Cas
systemwas tested for gene activation and silencing in prokaryotes
(Bikard et al., 2013) and human pluripotent stem cells (hPSCs;
Kearns et al., 2013). In Escherichia coli, dCas9, fused to an RNAP
omega subunit that stabilizes RNAP at the proximal promoter,
increased β-galactosidase activity in a reporter system by∼three-
fold (Bikard et al., 2013). In hPSCs, one sgRNA increased
endogenous gene expression (SOX17) by 287-fold (Kearns et al.,
2013), which was the highest fold increase with one sgRNA in
CRISPR/dCas9 applications reported to date in any human cell
line or prokaryote. This finding might implicate that distinct
regulatory landscapes and mechanisms in different cell lines
determine the performance of dCas9 and that CRISPR/dCas9
may be useful to differentiate hPSCs to various types of somatic
cells.
Still, when considering effective gene regulation, maximizing
the inherent function of each reagent appears to be the best
route. In all studies that we have reviewed as of 2015, excepting
the report by Kearns et al. TALEs showed a better efficiency in
activating endogenous gene expression than did CRISPR/dCas9
in both one and multiple TALE-monomer/sgRNA applications.
Gao et al. investigated the efficiency of gene activation between
a TALE construct and four different constructs of dCas9
which targeted enhancer regions in Oct4 and Nanog loci
(Gao et al., 2014). The report showed that a TALE monomer
activated either reporter or endogenous genes significantly
better than did any construct of dCas9 with one sgRNA (Gao
et al., 2014). Importantly, Gao et al. increased the rigor of
the experiment from reporter expression to endogenous gene
expression and to cellular reprograming differentiating mouse
embryonic fibroblasts (MEFs) to iPSCs. dCas9s could not
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produce any reprogrammed cell colonies even though they could
increase the reporter and endogenous gene expression, whereas
TALEs produced reprogrammed iPSC colonies (Gao et al., 2014).
On the other hand, dCas9 constructs had equivalent or better
activity in silencing gene expression than did a TALE monomer
(Gao et al., 2014). Gao et al. speculate that the innate steric
hindrance that dCas9 shows at the target locus might interfere
with the endogenous transcription factor machinery, limiting the
capacity of dCas9 to activate gene expression.
Such strengths of dCas9 in silencing gene expression had been
shown in an early study in which dCas9 without a repressor
domain could override the effect of doxycycline-inducible rtTA
(tetracycline transactivator) targeting the same tet operator
sequence as the sgRNA (Gilbert et al., 2013). The potent gene
repression by dCas9 has been applied tomodify the lac regulatory
pathway in E. coli (Qi et al., 2013), to reprogram complex
biological pathways in yeasts (Zalatan et al., 2015), and to
build two-hybrid regulatory circuits with the Gal4 system in
mammalian cells (Kiani et al., 2014).
Modification of Regulatory Elements and
Epigenetic Environment
In addition to the direct regulation of transcription, one can
target and modify epigenetic environments and chromatin
organizations to investigate important mechanisms of neuronal
function. For example, TALEs fused to LSD1 histone demethylase
demethylated histones at endogenous enhancer loci and
subsequently down-regulated expression of the genes under the
control of the targeted enhancer in human cell lines (Mendenhall
et al., 2013). In another example, investigations from the
Gersbach group using dCas9 fused to an effector domain showed
robust modification of histone epigenetic markers. Hilton et al.
fused dCas9 to the catalytic domain of human acetyltransferase
p300 and observed robust up-regulation of H3K27 acetylation
(four- to eight-fold) and of target gene expression (5- to 265-fold;
Hilton et al., 2015). Thakore et al. investigated effects of KRAB
repressor in epigenetic landscape and found enriched H3K9
trimethylation specifically at the target locus (HS2 enhancer)
and consequent gene silencing of multiple globin genes under
control of HS2 (Thakore et al., 2015). In addition to histone
modifications, the methylation status of DNA contributes to the
epigenetic environment. TET1 hydroxylase is responsible for
the first step of 5-methylcytosine demethylation, which often
activates a promoter (Shin et al., 2014b). This, too, can be
modified with PDBAs, and targeted demethylation of CpGs in
the promoter by TALEs fused to a TET1 hydroxylase catalytic
domain increased the expression in endogenous target loci in
human cells (Maeder et al., 2013a).
The genome has higher organizational structures beyond
localized epigenetic environments. The multigene complex is
one of the higher organizations and represents the locus on
the genome where multiple genes on the same or different
chromosomes associate with RNA polymerase (RNAP). The
transcription of these multiple genes can be synchronously
controlled at this multigene complex. Introducing mutations
to a multigene complex using TALENs disrupted gene loop
formation and significantly decreased gene expression (Fanucchi
et al., 2013). Targeting Cas9 with two sgRNAs to the regulatory
sequences, Li et al. demonstrated that efficient inversions and
duplications of the regulatory elements and gene clusters can be
induced in human cells and mice by inducing 2–4 DNA DSBs
separated by a few tens of bases to several hundred kilo bases (Li
J. et al., 2015). This perturbation was transmitted to offspring and
led to the discovery of a new regulatory role of the protocadherin
gamma gene cluster.
VISUALIZATION
Besides specific manipulation of genomic sequences, PDBAs
can be adapted to visualize the native organization of the
chromatin. Alterations in DNA structures are implicated in
multiple trinucleotide repeat disorders such as Huntington’s
disease and spinocerebellar ataxia (Kovtun et al., 2001) as well
as hexanucleotide (GGGGCC) repeats in amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD; Haeusler
et al., 2014). Using new PDBA reagents, genome organization in
these disorders may be visualized in live cells. Using TALEs fused
to fluorescent proteins (TALE-FP), Ma et al. imaged repetitive
DNA sequences in the telomere of live or fixed human cells
(U2OS cells; Ma, H. et al., 2013b). A specific chromosome was
identified using centromeric repeat sequences specific to the
particular chromosome (Ma, H. et al., 2013b). Miyanari et al.
used TALE-FP to show that paternal and maternal chromosomes
could be differentially labeled and visualized in live mouse cells
and embryos using single nucleotide polymorphisms (SNPs)
in the chromosomes due to the extreme sequence specificity
of TALEs (Miyanari et al., 2013). Using a dCas9 system fused
to fluorescent proteins and capitalizing on the strength of the
CRISPR/dCas9 system for multiplexing, Chen et al. visualized
non-repetitive genomic sequences by “tiling” sgRNA along the
target locus (Chen et al., 2013). All three studies imaged
changing chromosomal organizations at each cell cycle. It is not
known whether and how post-mitotic neurons change genomic
conformation. The three studies indicate that the structural and
organizational understanding of the genome in neurons could be
done in vivo.
OFF-TARGET EFFECTS
In each application of PDBAs, a strategy to identify off-target
effects needs to be in place. Despite the precision that the PDBA
systems have shown, it is imprudent to expect any PDBA to
bind to one unique locus in the genome. Plant pathogenic
bacteria in the genus Xanthomonas evolved type III secretion
system delivering TALEs into plant cells to induce expression
of the host genes beneficial to their survival (Yang and White,
2004; Gu et al., 2005). Several off-targets in DNA binding
would not have compromised the purpose of the system. When
bacteria detect foreign viral DNA sequences registered in their
CRISPR sequences (Ishino et al., 1987; Barrangou et al., 2007;
Garneau et al., 2010), a few mismatches might be tolerated
as far as the exogenous DNAs are effectively cleaved in the
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same way the restriction endonuclease system has evolved in
bacteria. Thus, the specificity of targeting a locus in the genome
is a primary concern that arises with the adaptation of the
biological systems to human needs, in particular, for therapeutic
purposes. In most research systems, off-target effects of PDBAs
can be ruled out by generating two independent mutant alleles
in which a genotype-phenotype relationship is confirmed. In
animal models, potentially undetected off-target effects can be
diluted out through chromosomal shuﬄing during meiosis. In
cell culture models, two clones with the same mutation can be
chosen to ensure the phenotype appears due to the mutation.
With therapeutic and clinical applications, the system needs
to be highly specific. If a PDBA system is used somatically to
alter DNA sequences in differentiated adult cells, the change
is permanent in the individual. In germ-line applications, the
changes to the genetic material are permanent and heritable.
These serious implications in clinical applications need to be
considered, but it is equally important to see that there are
different levels of stringency for precision depending on the
nature of the experiments planned. Therefore, for researchers
who plan to use a PDBA system, their experimental purposes
are the most important consideration when choosing a PDBA
system. For genome engineering as a discipline, researchers have
most intensely investigated two areas as they aim to develop
therapies with PDBAs: one to improve the specificity of the
system and the other to detect off-target sites and effects.
Statistically, a CRISPR/Cas or TALE (monomer with 15-
RVDs) system can incur off-target effects (cleavage or altered
expression), although a TALEN (15-RVDs× 2) system may offer
unique binding even in large mammalian genomes including the
human’s. An sgRNA in the CRISPR/Cas system can encounter
a binding sequence by chance every 412 bases (∼1.5 × 107)
to 414 bases (∼2.5 × 108), taking into account two specific
nucleotides in the PAM sequence (nGG) and 10–12 nt of seed
sequences immediately upstream of the PAM sequence within
a 20-nt sgRNA. This results in 11–179 potential binding sites
in a human haploid genomic sequence (∼3 gigabases) assuming
random genomic sequences.Mismatches are tolerated even in the
seed sequences in the sgRNA, which increases the chance of off-
target binding of Cas9 further. A 15-RVD based and dimerized
TALEN system would encounter a binding site every 430 bases
(∼1.0 × 1018), which suggests the possibility of a unique target
site in the human haploid genome. However, since the binding of
each RVD is not completely exclusive to one nucleotide, TALENs
also have detectable off-target effects (Hockemeyer et al., 2011;
Fine et al., 2014).
Statistical probability notwithstanding, experimentally-
determined data on off-target effects of the CRISPR/Cas
system have been different from that of bioinformatics
predictions. Methods to identify off-target effects have evolved
from sequence-based computational prediction to genome-
wide identification of Cas9-binding sites with chromatin
immunoprecipitation (ChIP), and later to genome-wide
interrogation of DNA cleavage (for a review, see Ishida et al.,
2015; Koo et al., 2015; O’Geen and Yu, 2015). Sequenced
genomes allow direct comparison of the nucleotide sequences of
designed sgRNAs, identifying predictable off-target binding sites.
This bioinformatic identification of off-target sites was the basis
of early studies in which these selected sites were monitored
with reporter systems and sequenced (Cradick et al., 2013; Hsu
et al., 2013; Pattanayak et al., 2013; Mali et al., 2013a; Cho et al.,
2014; Fu et al., 2014). The off-target binding and DNA cleavage
resulting from these studies varied widely—depending on the
target site and sgRNAs—from no off-target sites to ∼10 sites
for each sgRNA. It is not clear if this is a site-specific epigenetic
environmental effect, sgRNA sequence effect, or something
else. After this selected investigation of off-target effects, more
unbiased approaches were developed. These investigations
utilized RNA sequencing (Gilbert et al., 2013; Perez-Pinera et al.,
2013a) or ChIP followed by sequencing (Cencic et al., 2014;
Kuscu et al., 2014; Wu et al., 2014; Polstein et al., 2015). To
investigate the binding of Cas9 protein to the target locus, a
modified version of dCas9 was used with ChIP-seq applications.
It was hypothesized that since dCas9 does not cleave the DNA
and stays bound, it would generate unbiased genome-wide
snapshots unmasked by potentially varying efficiency of DNA
repair in different cell lines. The majority of the studies found
a highly enriched binding to the target sites and highly specific
gene expression patterns (0 or 1 off-target binding sites), yet there
was identifiable off-target binding (up to a few hundred sites) for
some sgRNAs as well. These methods presented two challenges.
First, it was difficult to functionally determine if the binding
of dCas9 changed gene expression since sequence mutations
were absent. A threshold has to be arbitrarily set to interpret if
the changes in gene expression were significant. Second, this
method also captured transient binding of dCas9 to the genomic
DNA. The mechanism of Cas9-DNA binding suggests that Cas9
scans the genome for the PAM sequence (5′-NGG-3′) and that
there is transient binding depending on the degree of sequence
matching between the sgRNA and genomic DNA sequence
(Anders et al., 2014). Thus, the off-target binding of dCas9 might
not be off-target events but merely the locus of dCas9 at the
moment of the assay.
Overcoming these limitations, unbiased DNA cleavage event-
based methods were developed. These methods integrate DNA
double-strand break (DSB) events with insertion of reporters
or capturing of the broken fragments with adaptors. IDLV
(integrase-defective lentiviral vector), GUIDE (genome-wide,
unbiased identification of DSBs enabled by sequencing), and
BLESS (direct in situ breaks labeling, enrichment on streptavidin
and next-generation sequencing) methods make use of lentivirus
integration, double-strand oligo deoxyribonucleotide (dsODN),
or streptavidin as a DSB capture device, respectively (Tsai et al.,
2014b; Ran et al., 2015; Wang et al., 2015). While the strength of
these methods is that DNADSBs are captured, their shortcoming
is that it might capture DSB events that are independent of
PDBA-induced breaks. More recently, two technologies provided
an improved way of identifying PDBA activities. O’Geen et al.
co-opted a ChIP-seq based method to enrich significant dCas9-
binding signal by designing capture probes (O’Geen et al., 2015).
Kim et al. developed a system to identify off-targets without
any capture devices by re-digesting Cas9-treated genomic DNA
with Cas9 in vitro (Kim et al., 2015). These unbiased approaches
find that CRISPR/Cas systems are specific, making one off-target
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cut in the whole genome when appropriately designed sgRNAs
were used (O’Geen et al., 2015). For an sgRNA to be deemed
appropriately designed, the sgRNA has to be unique in the
genome bymore than four nucleotides compared to potential off-
target sites. However, there are cases of sgRNAs that led to several
tens off-target sites despite the apparent soundness of the design
(Tsai et al., 2014b; Kim et al., 2015; Ran et al., 2015; Wang et al.,
2015). In addition, these methods confirmed that computational
sequence predictions are different from actual off-target cleavage
sites and that dCas9-binding sites are different from actual off-
target cleavage sites. Some reasons for the differences identified
are sequence variation in the sample (Yang et al., 2014) and
DNA or sgRNA bulging at the target sites (Lin et al., 2014).
These studies demonstrate that while CRISPR/Cas systems have
clear off-targeting effects, they rarely have the spurious off-target
sites that bioinformatic methods predicted. However, further
optimization is absolutely required to adapt CRISPR/Cas systems
for therapeutic purposes, as zero off-target sites is the expectation
for clinical applications.
Efforts to increase the specificity of CRISPR/Cas9 systems
have attempted various strategies. Optimized sgRNA designs
such as shorter sgRNAs (17–18 nts) truncated at the 5′-end
of conventional 20 nt sgRNAs (Fu et al., 2014) or addition of
two guanine nucleotides at the 5′-end of sgRNAs (Cho et al.,
2014) significantly decreased off-target effects. Cas9 has been
engineered to make Cas9 variants with either endonuclease
domain, RuvC or HNH, inactivated (Jinek et al., 2012). A pair
of Cas9 nickases targeted to adjacent sites on opposite strands
results in DNA DSBs with significantly reduced off-target effects
(Ran et al., 2013; Mali et al., 2013a; Cho et al., 2014; Frock
et al., 2014; Shen et al., 2014). In a similar pairing scheme, a
dCas9 protein with nuclease domains inactivated is fused to FokI
endonuclease, as FokI dimerization is required to make DNA
DSBs. The dCas9-FokI systems showed significantly improved
specificity (Tsai et al., 2014a; Guilinger et al., 2014b; Wyvekens
et al., 2015). A disadvantage of nickase and dCas9-FokI systems
is that the pairing requirement decreases the number of available
target sites in a genome since two closely located PAM sequences
are needed.
Most recently, two groups independently reported engineered
S. pyogenes Cas9 (SpCas9) systems that show significantly
decreased off-target effects using current unbiased genome-
wide off-target screening technologies. Both groups optimized
the energetics during the formation of target DNA-guide
RNA-SpCas9 complex by decreasing non-specific interactions
between SpCas9 protein and target DNA while maintaining
specific interactions between guide RNA and the complementary
strand of target DNA (Kleinstiver et al., 2016; Slaymaker et al.,
2016). Slaymaker et al. focused on the non-specific electrostatic
interactions between the negatively charged phosphate backbone
of the non-complementary strand of target DNA and the
positively charged amino acid residues in SpCas9 protein in
the groove between two nuclease domains (Slaymaker et al.,
2016). Three engineered SpCas9 variants [SpCas9 (K855A),
eSpCas9(1.0) (K810A/K1003A/R1060A), and eSpCas9(1.1)
(K848A/K1003A/R1060A)] showed undetectable off-target
effects at three previously identified off-target sites using next
generation sequencing in human cell cultures (Slaymaker
et al., 2016). When all known off-target sites were investigated,
eSpCas9(1.0) and eSpCas9(1.1) showed a significantly decreased
cleavage rate (<0.2% indel) in 22 out of 24 sites. In BLESS
assessments for unbiased genome-wide off-target screening,
there were still noticeable indels while reduction in off-target
cleavage was clear compared to wild-type Cas9. BLESS only
detected 1.0 and 0.7% indels at two EMX1(1) off-target sites
(OTs) and 2.5, 6.3, 14.7, and 25.5% at four VEGFA(1) OTs for
SpCas9 (K855A). eSpCas9(1.1) showed no discernable indels
at EMX1(1) and 0.3 and 27.0% indels at two VEGFA(1) OTs.
The three SpCas9 variants [SpCas9 (K855A), eSpCas9(1.0), and
eSpCas9(1.1)] maintained on-target indel efficiency comparable
(30–160%) to wild-type SpCas9 assessed with 24 sgRNAs in 10
endogenous loci (Slaymaker et al., 2016).
While Slaymaker et al. focused on non-complementary DNA
strand and electrostatic interactions, Kleinstiver et al. engineered
the Cas9 amino acid residues that make non-specific contact with
complementary DNA strand to sgRNA through hydrogen bonds
(Kleinstiver et al., 2016). Kleinstiver et al. abrogated hydrogen
bonding between the Cas9 residues (N497, R661, Q695, and
Q926) and the phosphate backbone of the complementary strand
of target DNA by replacing those residues with alanine residues.
When assessed with GUIDE-seq for unbiased genome-wide off-
target detection, the Cas9 variant, SpCas9-HF1, with all four
residues replaced with alanine, showed a complete absence of
off-target effects with seven sgRNAs in four endogenous loci in
human cells and only one detectable off-target effect. Subsequent
next generation sequencing of 36 wild-type Cas9 OTs identified
in GUIDE-seq showed that SpCas9-HF1 had only a background
level of indels at 34 out of 36 OTs and negligible indel rates
of 0.049 and 0.037% at the other two OTs (Kleinstiver et al.,
2016). SpCas9-HF1 maintained on-target mutagenic efficiency
comparable (70–140% excluding one sgRNA with no activity)
to wild-type Cas9 with 12 sgRNAs in five endogenous loci
(Kleinstiver et al., 2016).
The differences in off-target effects between the two structure-
guided protein engineering studies might come from varying
sensitivity of genome-wide screening technologies (BLESS vs.
GUIDE-seq). Importantly, these two studies demonstrated
that rational protein engineering can improve specificity in
CRISPR/Cas systems. Along with off-target detecting techniques
and engineered Cas9 proteins, sgRNA designing software is
evolving, which may further decrease off-target effects through
design of higher-specificity sgRNAs (Bae et al., 2014b; Montague
et al., 2014; Xie S. et al., 2014b; Moreno-Mateos et al., 2015).
Although statistics and bioinformatics predict that TALENs
are highly specific, TALENs also have off-target effects. With
optimization of the system, the number of off-target sites have
significantly decreased (Osborn et al., 2013; Ousterout et al.,
2013; Guilinger et al., 2014a). A study showed that the 5′-
side of TALEN-binding site (N-term side of TALENs) is more
influential in determining TALEN specificity and found that for
higher activity and specificity, the first two bases should not
be adenine-adenine or cytosine-adenine (Meckler et al., 2013;
Juillerat et al., 2014). The degree of individual RVD specificity was
also studied. All classic RVDs (NI:A, HD:C, NN:G, and NG:T)
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do not bind exclusively to one base; rather, RVDs have degrees
of discriminating power among the four bases rather than an
RVD exclusively binds to a base. For example, HD conventionally
binds to cytosine (C) and discriminates C from adenine, guanine,
and thymine with scores of 0.06, 0.80, and 0.47, respectively
(where 1.00 represents perfect discrimination; Juillerat et al.,
2015). This limited specificity led to the development of non-
conventional RVDs to improve the specificity of TALENs
targeting the same locus. In a different approach using modified
phage display and protein evolution systems, Hubbard et al.
developed a directed protein evolution system in which the
DNA binding domain of TALENs can be rapidly optimized
for an improved specificity (Hubbard et al., 2015). It is now
critical to apply unbiased genome-wide screening developed for
CRISPR/Cas9 systems to TALEN off-target screening to validate
that directed protein evolution and non-conventional RVDs do
indeed decrease off-target effects.
Acknowledging that none of the PDBAs are absolutely specific
is important because it will facilitate investigations to improve
specificity and detect off-target effects. As a practical guideline,
any investigation using PDBAs should use an alternative design
(two target sites against a locus) to show the genotype-phenotype
relationship beyond doubt. In addition, large-scale projects
should be mandated to employ at least one unbiased off-target
screening method to show that the PDBA used is reasonably
specific without any spurious off-target effects. Lastly, if the
system is an animal model, F2 or later generations rather
than F1s should be used to ensure the dilution of non-specific
mutagenesis. If enough cautions are used, PDBAs are already
precise enough to accommodate most (if not all) of research
needs. For therapeutic applications, any PDBA systems will need
to be further optimized. However, if the absence of off-target
effects is shown in cell culture systems and animal models, the
particular PDBA design that targets a specific locus may be tested
in human subjects.
CONCLUSIONS AND PERSPECTIVES
New generations of programmable DNA-binding agents
(PDBAs) such as TALE and CRISPR/Cas systems have rapidly
materialized highly efficient genome engineering systems.
PDBAs can now target nearly any locus in the genome,
introduce or correct mutations, modulate gene expression,
and change epigenetic environments with a controllable
level of off-target effects, which provides unprecedented
opportunities to understand neuronal and neuropsychiatric
disorders. These PDBA technologies are being incrementally
introduced in neuroscience, and there are only a small number
of investigations that focus on the effects and outcomes
of PDBA application in the nervous system. Considering
distinctive mechanisms of DNA double-strand break repair
and epigenetic regulation in neurons, we need more studies
to complete our understanding of the functions and effects of
applying PDBAs in the nervous system. To access the central
nervous system, delivery mechanisms will need to be further
engineered (Holkers et al., 2014; Ain et al., 2015; Chen and
Gonçalves, 2015). To achieve cell-line specific inducible PDBA
systems, neural populations and cell-line specific promoters
need to be better characterized to avoid false outcomes
(Forni et al., 2006; Galichet et al., 2010). In spite of these
outstanding challenges, PDBAs will be a pivotal technology
that will lead to new understanding and drive innovations in
neuroscience.
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